Persistence of Novel First-Line Antiretroviral Regimes in a Cohort of HIV-Positive Subjects,Coris 2008–2010

Palella F.J. Jr. , Delaney K.M. , Moorman A.C. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–860.

Jaggy C. , von Overbeck J. , Ledergerber B. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362: 877–878.

Thompson M.A. , Aberg J.A. , Cahn P. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321–333.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 10 January 2011. Accessed 19 December 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Panel de expertos de GESIDA y Plan Nacional sobre el Sida. [National Consensus Document by GESIDA/National AIDS Plan on Antiretroviral Treatment in Adults Infected by the Human Immunodeficiency Virus]. Spanish. (Updated January 2011. Accesssed 19 December 2011.) Available from http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2011-Documentoconsenso-TAR-adulto-verordenador.pdf.

Sobrino-Vegas P. , García-San Miguel L. , Caro-Murillo A.M. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009; 7: 224–230.

Sobrino-Vegas P. , Rodríguez-Urrego J. , Berenguer J. Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care. Antivir Ther 2012; 17: 1–8.

Palella F.J. Jr. , Chmiel J.S. , Moorman A.C. , Holmberg S.D. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16: 1617–1626.

Cicconi P. , Cozzi-Lepri A. , Castagna A. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort ofantiretroviral-naive patients. HIV Med 2010; 11: 104–113.

Vo T.T. , Ledergerber B. , Keiser O. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197: 1685–1694.

Sabundayo B.P. , McArthur J.H. , Langan Sj , Gallan J.E. , Margolick J.B. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection. Pharmacotherapy 2006; 26: 674–681.

Yuan Y. , L'Italien G. , Mukherjee J. , Iloeje U.H. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006; 7: 156–162.

Palacio H. , Li X. , Wilson T.E. Healthcare use by varied highly active antiretroviral therapy (HAART) strata: HAART use, discontinuation, and naivety. AIDS 2004; 18: 621–630.

Cramer J.A. , Roy A. , Burneti A. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44–47.

Bae J.W. , Guyer W. , Grimm K. , Altice F.L. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011; 25: 279–290.

Willig J.H. , Abroms S. , Westfall A.O. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22: 1951–1960.

Sobrino-Vegas P. , Gutierrez F. , Berenguer J. The cohort of the Spanish HIV research network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up. Enferm Infecc Microbiol Clin 2011; 29: 645–653.

Prentice R.L. , Kalbfleisch J.D. , Peterson A.V. Jr. , Flournoy N. , Farewell V.T. , Breslow N.E. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541–554.

Putter H. , Fiocco M. , Geskus R.B. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 2389–2430.

Geskus R.B. Cause-specific cumulative incidence estimation and the Fine and Gray model under both left truncation and right censoring. Biometrics 2011; 67: 39–49.

Fine J.P. , Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

Lau B. , Cole S.R. , Gange S.J. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009; 170: 244–256.

Mocroft A. , Youle M. , Moore A. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15: 185–194.

d'Arminio Monforte A. , Cozzi Lepri A. , Rezza G. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14: 499–507.

Elzi L. , Marzolini C. , Furrer H. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170: 57–65.

Juday T. , Grimm K. , Zoe-Powers A. , Willig J. , Kim E. A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. AIDS Care 2011; 23: 1154–1162.

Maggiolo F. , Leone S. , Cologni G. , Valenti D. , Quinzan G. , Suter F. Persistence on first line HAART is influenced by dosing schedule. XVIII International AIDS Conference. 18–23 July 2010, Vienna, Austria. Abstract 178.

Maggiolo F. , Arici C. , Airoldi M. Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. J Antimicrob Chemother 2007; 59: 569–572.

Bongiovanni M. , Cicconi P. , Landonio S. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents 2005; 26: 88–91.

Reekie J. , Reiss P. , Ledergerber B. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Med 2011; 12: 259–268.

Smith C.J. , Olsen C.H. , Mocroft A. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS 2008; 22: 47–56.

Lichtenstein K.A. , Delaney K.M. , Armon C. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32: 48–56.

Curkendall S.M. , Richardson J.T. , Emons M.F. , Fisher A.E. , Everhard F. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2007; 8: 483–490.

Kelleher T. , Cross A. , Dunkle L. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine. Clin Ther 1999; 21: 1182–1192.

Uy J. , Yang R. , Thiry A. Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated with atazanavir/r and lopinavir/r in the CASTLE study. J Int AIDS Soc 2008; 11: 8.